Minako Yamamura, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiocarcinoma | 4 | 2021 | 563 | 0.790 |
Why?
|
| Bile Duct Neoplasms | 4 | 2021 | 617 | 0.690 |
Why?
|
| CDC2 Protein Kinase | 1 | 2019 | 212 | 0.630 |
Why?
|
| Beriberi | 1 | 2016 | 6 | 0.540 |
Why?
|
| Pericardial Effusion | 1 | 2016 | 246 | 0.450 |
Why?
|
| Caroli Disease | 2 | 2021 | 12 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 5709 | 0.270 |
Why?
|
| Receptor, Notch2 | 1 | 2021 | 90 | 0.180 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2018 | 31 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2021 | 10494 | 0.130 |
Why?
|
| Cysts | 1 | 2021 | 685 | 0.130 |
Why?
|
| Thiamine | 1 | 2016 | 160 | 0.120 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 770 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2021 | 1307 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 2331 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 2930 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2019 | 2942 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3619 | 0.090 |
Why?
|
| Piperazines | 1 | 2021 | 2546 | 0.090 |
Why?
|
| Pyridines | 1 | 2021 | 2888 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2021 | 304 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4362 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2017 | 1494 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2019 | 8332 | 0.080 |
Why?
|
| Dyspnea | 1 | 2016 | 1352 | 0.070 |
Why?
|
| Cell Movement | 1 | 2019 | 5223 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2022 | 3523 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2019 | 10125 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2016 | 4202 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11249 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8635 | 0.050 |
Why?
|
| Echocardiography | 1 | 2016 | 5043 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 17149 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 9182 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2021 | 190 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 379 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2021 | 699 | 0.040 |
Why?
|
| Veratrum Alkaloids | 1 | 2018 | 23 | 0.040 |
Why?
|
| Xenopus Proteins | 1 | 2021 | 436 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 352 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 467 | 0.040 |
Why?
|
| Purines | 1 | 2021 | 614 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 59680 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2021 | 673 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 564 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 2017 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 578 | 0.040 |
Why?
|
| Printing | 1 | 2017 | 47 | 0.030 |
Why?
|
| Bile Ducts | 1 | 2018 | 288 | 0.030 |
Why?
|
| Middle Aged | 4 | 2021 | 223418 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 726 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 604 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2018 | 454 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2021 | 864 | 0.030 |
Why?
|
| Mice | 2 | 2021 | 82045 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2017 | 616 | 0.030 |
Why?
|
| Solvents | 1 | 2017 | 298 | 0.030 |
Why?
|
| Liver | 2 | 2021 | 7575 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 11138 | 0.030 |
Why?
|
| Retinal Vessels | 1 | 2021 | 864 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2021 | 954 | 0.030 |
Why?
|
| Male | 5 | 2021 | 364781 | 0.030 |
Why?
|
| Animals | 3 | 2021 | 169418 | 0.030 |
Why?
|
| Adult | 4 | 2022 | 223542 | 0.030 |
Why?
|
| Humans | 8 | 2022 | 768451 | 0.030 |
Why?
|
| Aged | 3 | 2021 | 171520 | 0.030 |
Why?
|
| Japan | 1 | 2017 | 1418 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 2062 | 0.020 |
Why?
|
| Cell Survival | 1 | 2021 | 5801 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 2819 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1104 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 2964 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 1950 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2017 | 988 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 65409 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3697 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 3734 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3939 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2021 | 23638 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2017 | 1818 | 0.020 |
Why?
|
| Female | 3 | 2021 | 396943 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2021 | 11674 | 0.010 |
Why?
|
| Phenotype | 1 | 2021 | 16712 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 19041 | 0.010 |
Why?
|
| Rats | 1 | 2018 | 23839 | 0.010 |
Why?
|
| Apoptosis | 1 | 2017 | 9526 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 30028 | 0.010 |
Why?
|